Shenzhen New Industries Biomedical Engineering Co Ltd

The company maintains a strong liquidity position, with a current ratio of 8.98, indicating a high ability to meet short-term obligations. Free cash flow of 478.77 million CNY and operating cash flow of 1.52 billion CNY further support its liquidity profile. However, the risk assessment notes that net cash is negative after subtracting total debt, suggesting potential short-term liquidity constraints. Profitability metrics are robust, with a return on equity (ROE) of 17.72% and a return on assets (ROA) of 16.3%, both exceeding the typical thresholds for the medical equipment industry. The gross profit margin of 69.2% (calculated from gross profit of 3.17 billion CNY on revenue of 4.58 billion CNY) indicates strong pricing power and cost control. Geographic and segment exposure is not explicitly detailed in the available data, but the company operates primarily in China, with no disclosed international revenue. Revenue concentration is not specified, but the absence of segment breakdowns suggests a relatively undiversified business model. The company’s growth trajectory is not explicitly outlined in the financial data, but the strong operating income of 1.88 billion CNY and net income of 1.62 billion CNY suggest a stable and profitable business. Analysts have assigned a mean price target of 67.61 CNY, with a median of 67.00 CNY, and a mean recommendation of 1.64, indicating a generally positive outlook. Risk factors include the company’s low debt-to-equity ratio of 0.0, which suggests minimal leverage but may also indicate limited financial flexibility. The risk assessment classifies liquidity as medium and dilution as low, with no immediate pressure from share issuance or capital raising. Recent events include analyst estimates and price targets, with 5 strong-buy and 9 buy recommendations, and no hold or sell ratings. No recent filings or transcripts are available in the provided data to indicate material changes in operations or strategy.